During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

The diagnosis of a suspected lung, head, and neck cancer called NUT carcinoma should include additional testing capable of detecting gene fusions that are definitive markers of the disease, according ...

Dana-Farber research uncovered the potential for underdiagnosis of this aggressive cancer and identified additional tests ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

The system can predict the risk of hepatocellular carcinoma recurrence with 82 per cent accuracy. Read more at ...

Chekuri, V. and Trotter, G. (2025) Case Report: A Diagnostic Odyssey Unveiling BCGosis in an Elderly Patient. Case Reports in ...

An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.

With EAGLE, lung cancer biopsy analysis is expedited, accurately predicting EGFR mutations and streamlining the diagnostic process for better patient outcomes.

Drs. Fatemeh Ardeshir-Larijani and Mohamed Abazeed discuss a validated AI model that can predict how patients with advanced NSCLC will respond to immunotherapy.

SAN ANTONIO, July 09, 2025--bioAffinity Technologies' CyPath® Lung detects Stage 1A lung cancer when imaging was inconclusive ...